NCT07691762
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
See at-risk trials from Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Sep 2026 to Nov 2026
- Primary and study completion pushed from Apr 2031 to Sep 2031
Notable Start date: Jul 2026 to Sep 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Interventions modified
- Study sites: 1 to 2
- Secondary endpoints revised (9)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression-free survival (PFS) assessed by investigator
Timeframe: Until progression, assessed up to approximately 2 years.
Secondary (9)
Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
Overall survival (OS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of objective tumor response (DoR)
Show 4 moreShow less
Adverse events (AEs)
Serious adverse events (SAEs)
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)
Arms and interventions
Treatment group AExperimental
SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE)
Treatment group BActive comparator
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE)
Treatment group CExperimental
SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE)
Drugs: SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab
Sites
2 sites in 1 country